Study Compares Liquid and Tissue Biopsies for Cancer Mutations
Researchers evaluated liquid biopsy against traditional tissue biopsy. They focused on detecting actionable mutations in advanced cancers. The team measured sensitivity and specificity across multiple patient groups. Results highlighted both strengths and limitations of each method.
Liquid biopsy uses blood samples to find circulating tumor DNA. Tissue biopsy requires direct sampling from the tumor. Scientists analyzed matched samples from patients with advanced solid tumors. They compared mutation detection rates for key therapeutic targets.
Liquid biopsy showed high specificity in most cases. It correctly identified mutations when they were present in blood. However, sensitivity varied by cancer type and mutation abundance. Some low-frequency variants remained undetected in plasma. In contrast, tissue biopsy captured a broader range of alterations.
Concordance rates differed across studies. High agreement appeared for common mutations such as EGFR and KRAS. Meanwhile, lower concordance occurred with heterogeneous tumors. Spatial differences inside tumors explained many mismatches. As a result, liquid biopsy sometimes missed mutations found only in certain tissue regions.
The analysis used standardized sequencing platforms. Researchers applied strict bioinformatics filters to reduce false positives. Statistical evaluation confirmed overall performance metrics. Moreover, liquid biopsy offered clear practical advantages. It allowed repeated testing with minimal patient risk.
Experts note that both methods serve complementary roles. Tissue biopsy remains essential for initial diagnosis and full molecular profiling. Liquid biopsy supports monitoring and detection of resistance mutations over time. Further studies should refine detection thresholds and expand to more cancer types.
This evaluation underscores the growing value of liquid biopsy. It also confirms the continued importance of tissue-based testing for accurate treatment decisions in advanced cancers.
CMP Bio World 